NSD-2 is crucial for AR activity in prostate cancer, promoting tumor growth and offering a potential therapeutic target for advanced prostate cancer treatment.
(Azacitidine + cedazuridine) by Taiho Oncology for Refractory Anemia With Ringed Sideroblasts: Likelihood of Approval
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes